| Budget Amount *help |
¥25,220,000 (Direct Cost: ¥19,400,000、Indirect Cost: ¥5,820,000)
Fiscal Year 2012: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
Fiscal Year 2011: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
Fiscal Year 2010: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
|
|---|
| Research Abstract |
The aim of this study was the establishment for a novel strategy of the treatment for osteoclast-associated bone diseases such as periodontitis-associated alveolar bone loss, rheumatoid arthritis and osteoporosis. We revealed that a novel Btk inhibitor suppressed osteoclast differentiation and function in vitro and in vivo. Furthermore, we also revealed that genetic inhibition of class IA PI3K in osteoclasts resulted in the inhibition of bone-resorbing activity of osteoclasts. Thus, this study showed that pathways that mediated by a tyrosine kinase Btk and a lipid kinase class IA PI3K in osteoclasts are good therapeutic targets in these diseases in this study.
|
